Option Care Health (OPCH) Q1 2026: $55M CID Headwind Forces Revenue Reset, Acute Growth Offsets Margin Pressure
Option Care Health’s first quarter exposed the full impact of chronic inflammatory disease (CID) patient attrition, triggering a $55 million gross profit headwind and a downward revenue revision, even as acute therapy growth and operational discipline preserved EBITDA guidance. Leadership is betting on commercial expansion and operational realignment to rebuild census and stabilize long-term growth. Investors should watch the pace of chronic recovery and acute momentum as the year unfolds.
Summary
- Chronic Therapy Reset: Loss of CID patients and unfavorable therapy mix forced a revenue guidance cut.
- Acute Strength Mitigates Margin Drag: High single-digit acute growth and cost controls offset chronic shortfall.
- Recovery Hinges on Execution: Commercial team expansion and operational focus aim to restore census and growth trajectory.
Performance Analysis
Option Care Health’s Q1 results revealed a clear split between robust acute therapy execution and significant headwinds in the chronic portfolio. Acute therapy revenue grew in the high single digits, outpacing market trends, and was supported by strong local partnerships, referral growth, and effective clinical transition processes. Acute therapies, urgent infusions often post-hospitalization, are hyper-local and require tight hospital integration—areas where OPCH continues to build competitive advantage.
In contrast, the chronic therapy segment, which includes recurring infusions for autoimmune and rare diseases, saw a decline in revenue due to a sharp drop in CID patient census and an unfavorable therapy mix. The company now estimates a $55 million gross profit headwind from the CID reset, nearly doubling prior expectations. Despite this, EBITDA and EPS landed within guidance, reflecting acute strength, cost controls, and SG&A discipline. Share buybacks and working capital improvements also supported EPS stability and cash flow, though overall growth lagged internal targets.
- CID Portfolio Drag: Patient attrition and biosimilar mix shift in CID therapies drove a 600 basis point revenue headwind.
- Acute Outperformance: High single-digit acute growth, above market, stabilized EBITDA and gross profit trajectory.
- Cost Control Cushion: SG&A growth managed at or below gross profit growth, with variable compensation reductions offsetting margin pressure.
The quarter’s results underscore a business in transition, balancing acute growth against chronic volatility, with near-term performance hinging on operational execution and census rebuild.
Executive Commentary
"The first quarter reflected mixed performance for our business. Adjusted EBITDA and adjusted EPS performance were aligned with our expectations, but our revenue growth of 1% did not meet our expectations. We had strong execution across our acute therapy portfolio, a transitional period for our chronic therapy portfolio, and continued focus on strategic initiatives that will better position us to win."
John Rademacher, President and Chief Executive Officer
"Gross profit dollars also declined slightly over last year due to the decline in chronic revenue... With clarity of the CID portfolio reset, we now estimate an approximately $55 million gross profit headwind for the year, which includes the additional patient loss John spoke about earlier."
Minal Sethna, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Acute Therapy as Growth Engine
Acute therapy, urgent infusion delivered post-hospitalization or during transitions of care, remains OPCH’s core growth engine. The company’s local responsiveness, hospital partnerships, and clinical innovation continue to deliver high single-digit revenue growth, well above market rates. This segment’s higher gross margin profile is helping to offset chronic segment volatility.
2. Chronic Portfolio Reset and Recovery
The chronic therapy segment, which includes autoimmune and rare disease infusions, is undergoing a reset due to Stelara, a key CID therapy, losing patients to biosimilars and competitors. The patient census drop and less favorable therapy mix have created an outsized, recurring revenue headwind. Leadership is expanding the commercial team and realigning resources to rebuild census and restore growth, but acknowledges recovery will be gradual given the annuity nature of chronic patients.
3. Operational and Commercial Realignment
Option Care is investing in commercial expansion, technology, and workflow enhancements to improve referral conversion rates, streamline admissions, and increase market share. Operational excellence initiatives target therapy-level economics and efficiency, while the ambulatory infusion clinic footprint is expanding, with 14% YoY growth in visits and 34% of nursing visits now conducted in clinics or suites.
4. Payer and Pharma Partnerships
Site-of-care initiatives with payers are outperforming expectations, delivering cost savings and member satisfaction, which strengthens OPCH’s value proposition. Pharma program development is progressing, with a pipeline of new infused and injectable drugs expected to drive future specialty growth, though some rare/orphan program launches have been delayed due to regulatory and commercial hurdles.
5. Capital Allocation Discipline
OPCH expanded its revolving credit facility from $400 million to $850 million, prioritizing organic investment, M&A in adjacent areas, and periodic share buybacks. This enhanced flexibility supports both near-term recovery and long-term growth ambitions.
Key Considerations
This quarter marks a strategic inflection for Option Care Health, as management pivots from chronic therapy headwinds toward operational and commercial recovery. Investors should focus on the following:
- Acute Growth Sustainability: Acute therapy outperformance is critical to offsetting chronic drag; watch for continued above-market growth and margin resilience.
- CID Census Rebuild Pace: The speed and effectiveness of patient retention and new referral conversion will determine chronic recovery trajectory.
- Commercial Team Execution: Expanded commercial resources and realigned coverage must translate into measurable patient and revenue gains.
- Cost Structure Flexibility: Ongoing SG&A discipline and variable compensation reductions are supporting margin stability, but long-term gains require revenue acceleration.
- Pharma and Payer Opportunity Capture: Execution on new drug launches and site-of-care partnerships will shape future specialty and chronic growth vectors.
Risks
Option Care faces ongoing risk from competitive share loss in chronic therapies, therapy mix volatility, and the potential for further biosimilar-driven disruption. Regulatory changes, payer formulary shifts, and delays in rare/orphan drug launches add uncertainty. While management claims the CID reset is “one time and done,” the chronic portfolio’s slow recovery and competitive intensity remain key watchpoints for future quarters.
Forward Outlook
For Q2 2026, Option Care Health expects:
- Sequential revenue growth in the mid-single digits over Q1
- EBITDA sequential growth in the high single digits
For full-year 2026, management revised guidance to:
- Net revenue of $5.675 billion to $5.775 billion (just over 1% growth)
- Maintained EBITDA guidance of $480 million to $505 million
- Adjusted EPS range of $1.82 to $1.92
Management cited confidence in acute momentum, cost controls, and a stable patient census post-reset as the basis for maintaining profit guidance. The team expects sequential growth each quarter, with a natural seasonal lift in the back half of the year, and no further CID headwinds carrying into 2027.
Takeaways
Option Care Health’s Q1 performance was defined by a chronic portfolio reset, but operational discipline and acute therapy strength preserved profit guidance.
- Chronic Headwind Now Quantified: The $55 million CID gross profit headwind is fully baked into guidance, with leadership focused on rebuilding census and therapy mix quality.
- Acute and IG Neuro Drive Margin Stability: High-performing acute and IG neuro segments are offsetting chronic drag and underpinning EBITDA resilience.
- Execution is Critical: Investors should monitor commercial team impact, referral conversion rates, and the pace of chronic recovery as the key variables for sustained growth.
Conclusion
Option Care Health enters the remainder of 2026 with a reset baseline and clear operational priorities. The path forward will be defined by the company’s ability to rebuild chronic census, sustain acute outperformance, and execute on commercial and operational initiatives. Margin preservation in the face of revenue headwinds reflects disciplined management, but long-term value creation depends on reigniting top-line growth.
Industry Read-Through
Option Care’s experience highlights the vulnerability of chronic infusion providers to biosimilar disruption, payer formulary shifts, and patient benefit design changes. The acute therapy segment’s resilience and local execution advantage signal opportunity for those able to partner effectively with hospitals and health systems. Industry-wide, expect continued margin pressure in chronic portfolios and a premium on operational agility, payer alignment, and specialty pipeline execution. Providers with diversified therapy portfolios and robust referral networks will be best positioned to weather volatility and capture share in a shifting infusion landscape.